Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin Alfa for Transfusion Reduction in Hip Replacement Surgery
NCT00269958Phase 2Completed
- Sponsor
- Janssen Ortho
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 2, randomised, double-blind trial of epoetin alfa in anemia (3 arms), sponsored by Janssen Ortho. Primary endpoints: Proportion of patients needing blood transfusions and Proportion of patients who develop anemia. Status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00269958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00269958.